Impax Laboratories appoints Paul M. Bisaro as CEO
With 25 years of generic and branded pharmaceutical experience, Mr. Bisaro served as Executive Chairman of Allergan, plc (formerly Actavis, plc), President and CEO of Actavis (formerly Watson Pharmaceuticals, Inc.) and Chairman of the Board.
Prior to joining Watson in 2007, Mr. Bisaro was President, Chief Operating Officer and a member of the Board of Directors of Barr Pharmaceuticals, Inc., a global specialty pharmaceutical company (Barr), from 1999 to 2007.
Between 1992 and 1999, he served as General Counsel of Barr, and from 1997 to 1999, served in various additional capacities.
Prior to joining Barr, Mr. Bisaro was associated with the law firm Winston & Strawn and a predecessor firm, Bishop, Cook, Purcell and Reynolds, from 1989 to 1992.
He also served as a Senior Consultant with Arthur Andersen & Co.
Mr. Bisaro currently serves on the board of directors of Allergan, Zoetis, Inc. and on the Board of Visitors of the Catholic University of America's Columbus School of Law.
He also serves on the Board of Zimmer Biomet Holdings, Inc. but has notified the board that he will not stand for re-election as a director at the company's 2017 annual meeting of stockholders.
Mr. Bisaro also served as Chairman of the Board of the Generic Pharmaceutical Association (GPhA) in 2010 and 2011.
Mr. Bisaro received his undergraduate degree in General Studies from the University of Michigan and a Juris Doctor from Catholic University of America in Washington, D.C. ■
LATEST MOVES FROM California
- Visa appoints John F. Lundgren as director
- MyoKardia appoints David Meeker to board
- Habit Restaurants appoints Douglas R. Branigan as CDO
- Michael Baker International promotes Bonnie D. Shepherd to EVP
- Comerica Bank names Andrew M. Bodisco president for East Bay
More inside POST
AIG board: No cash bonus for CEO Companies